Ligand (LGND) Pharmaceuticals announced the completion of its previously announced merger between the company’s wholly owned subsidiary, LNHC and CHRO Merger Sub, a wholly owned subsidiary of Channel Therapeutics Corporation. The combined company will operate under the name Pelthos Therapeutics and will commence trading on the NYSE American exchange under the new ticker symbol “PTHS” on July 2, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LGND:
- Ligand Pharma Elects Board Members at Annual Meeting
- Ligand price target raised to $145 from $142 at Oppenheimer
- Ligand Pharma’s Strong Q1 Performance and Strategic Moves Justify Buy Rating with $135 Price Target
- Ligand Pharmaceuticals Reports Strong Q1 2025 Revenue Growth
- Ligand Pharmaceuticals Reports Strong Q1 2025 Earnings